explore -WSS

explore

author：entertainment 2025-09-27 23:52:49 - browse：14963

Photo illustration of Fyodor Urnov surrounded by DNA strands. -- health coverage from STAT — Christine Kao/STAT

Researchers attending gene therapy meetings over the past couple years were liable to bump into a svelte, graying scientist explaining in emphatic, Russian-inflected English that the U.S. was wasting the grand potential of CRISPR gene editing.

Fyodor Urnov, the scientist in question, estimates he gave the talk 30 to 40 times: to fellow researchers, pharma executives, Food and Drug Administration officials, congressional staff, journalists, patient advocates. “Anyone who would listen,” he says.

The problem was one of scale. Sure, for-profit companies were developing cures for a small handful of genetic diseases, such as sickle cell disease. But there were hundreds of devastating conditions that CRISPR might be able to cure but that no entity was seriously working on.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： FDA's Pazdur wants cancer trials to range beyond China alone

entertainment

WSS

Hundreds died while taking an arthritis drug, but nobody alerted patients

ASCO: Palliative care found as helpful given virtually as in person

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Scientific mystery highlights the blind spots in genomics databases

Young boy dies in trial for Pfizer Duchenne gene therapy

Four alarming medical procedures we’re glad history forgot

Wikipedia

explore

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Trial using CRISPR to edit HIV out of cells disappoints

The high cost of giving birth even with insurance

At ASCO, AstraZeneca reports strong data for breast cancer drug

The cancer drug shortage isn’t new — and neither are the solutions

Four alarming medical procedures we’re glad history forgot

The cancer drug shortage isn’t new — and neither are the solutions

Ultragenyx gene therapy for rare liver ailment succeeds in late

Malaria cases in Florida and Texas: Here’s what you need to know

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

explore

FDA's Pazdur wants cancer trials to range beyond China alone

NIH documents show early flaws of $1.6 billion long Covid program

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Bird flu in dairy cattle: New measures to control spread to humans

Scientific mystery highlights the blind spots in genomics databases

hotspot

entertainment

entertainment

knowledge